RATIONALE: The purpose of this study was to determine whether conventionally used ILC2 markers, ST2 and CD127, are sufficient to include all Th2-cytokine producing ILCs. We hypothesized that ST2-and CD127-negative ILC2 populations exist in mouse lung and that these nontraditional populations might be activated by the clinically relevant fungal allergen Alternaria, a known potent inducer of IL-33. METHODS: Mice were challenged intranasally with Alternaria alternata for three consecutive days, and 24 hours after the last challenge brochoalveolar lavage fluid and lungs were harvested for flow cytometric analysis, ELISA, and lung section staining. ILCs were identified by flow cytometry as CD45+Lineage-Thy1.2+ lymphocyte-sized cells and were separated into four subsets based on ST2 and CD127 expression. Intracellular cytokine and transcription factor staining were performed on the ILC populations. RESULTS: Th2 cytokine-producing ILCs were identified in all four subpopulations, regardless of ST2 and CD127 expression, as evidenced by high GATA-3, IL-5, IL-13 and ILC2 surface marker expression. Further, ILC2 cytokines and surface markers were upregulated following Alternaria challenge, irrespective of ST2 and CD127 expression. The four ILC subpopulations were also found in RAG2 knockout mice, which is supportive of their presence being T-cell independent. Some of the unconventional ILC2s also produced IFNg and IL-17A suggesting the existence of ILC2 plasticity in these populations. CONCLUSIONS: Unconventional ST2-and CD127-negative ILC2 populations exist in mouse lung and are further induced by Alternaria. Thus, future mouse ILC2 investigations should be aware of ILC2 populations that do not express ST2 and CD127. Vanderbilt University, Nashville, TN. RATIONALE: Sex hormones regulate asthma pathogenesis, providing a potential mechanism for female predominance in adult asthma. Group 2 innate lymphoid cells (ILC2) produce IL-5 and IL-13, enhancing allergic airway inflammation. While testosterone attenuated ILC2-mediated airway inflammation, the role of estrogen receptor (ER) signaling is unknown. We hypothesized that ERa signaling increases ILC2-mediated airway inflammation. METHODS: Female ERa-/-and WT littermate controls were intranasally challenged with Alternata alternata extract (Alt Ext, 7.5mg) or vehicle for 4 consecutive days. Lungs and bronchoalveolar lavage fluid (BALF) were harvested for ELISA, inflammatory cell differentials, or flow cytometry. Sorted lung ILCs from naive ERa-/-and WT mice were stimulated with IL-2 and IL-33 (10 ng/mL) plus CellTrace Violet for 3 days and proliferation was analyzed by flow cytometry. RESULTS: Alt Ext challenge increased endpoints in WT and ERa-/-mice compared to vehicle. One day following Alt Ext challenge, ERa-/-mice had decreased lung IL-5 and IL-13 protein expression and decreased eosinophil, neutrophil and macrophage infiltration in BALF compared to WT mice (n59-10 per group, p<0.05). The number, but not percentage, of IL-5+IL-13+ ILC2 was decreased in Alt Ext challenged ERa-/-mice compared to WT mice. One hour after Alt Ext challenge, IL-33 in BALF was also decreased in ERa-/-mice compared to WT mice. However, proliferation of sorted ILC2 from ERa-/-and WT mice, with equal concentration of IL-33, had no change in ILC2 proliferation. CONCLUSIONS: ERa signaling regulates IL-33 secretion, resulting in increased ILC2 proliferation and cytokines. These results show estrogen signaling enhances allergic airway inflammation. 
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